Literature DB >> 28975971

The relationship between serum CXCL16 level and carotid vulnerable plaque in patients with ischemic stroke.

G Jin1.   

Abstract

OBJECTIVE: We investigated the relationship between the serum macrophage chemokine ligand 16 (CXCL16) levels and the vulnerable carotid plaque in patients with ischemic stroke. PATIENTS AND METHODS: We successively selected 118 cases of patients with an initial diagnosis of acute ischemic stroke (time of onset < 72 h), recorded risk factors, including gender, age, family history, smoking, body mass index, blood glucose levels, blood lipid levels, average systolic pressure and diastolic blood pressure (DBP) and homocysteine levels. ELISA was used to detect the levels of serum CXCL16. GE-3000 color Doppler ultrasound diagnostic instrument was applied for the detection of the cervical artery (including a bilateral common carotid artery, internal carotid artery and external carotid artery) intima-media thickness (IMT), plaque number, size, nature (stable and vulnerable) and luminal stenosis rate. Delica EMS-9EBx2P type transcranial Doppler ultrasound (TCD) was used to detect micro-arterial micro-embolic signals (MES). Stroke, according to etiologic type, was divided into large artery atherosclerosis (LAA), small artery occlusion (SAA) and others.
RESULTS: Serum CXCL16 levels were not significantly correlated with sex, age, family history, smoking, BMI, blood glucose levels, blood lipid levels, mean systolic blood pressure, diastolic blood pressure, and homocysteine levels. Serum CXCL16 levels increased with an increase of IMT, plaque area and lumen stenosis rate. Serum CXCL16 levels of vulnerable plaques were significantly higher than those of stable plaques; differences were statistically significant (p<0.05). It has nothing to do with the number of atherosclerotic plaques. The levels of serum CXCL16 in MES positive group were significantly higher than that in MES negative group; differences were statistically significant (p<0.05). The serum CXCL16 levels of LAA patients were significantly higher than that of SAA and other types of patients; differences were statistically significant (p<0.05).
CONCLUSIONS: The levels of serum CXCL16 are not related to high-risk factors for acute stroke and closely related to characteristics of atherosclerotic plaque, micro-embolic signals and stroke subtypes.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28975971

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  Association of Biomarker Level with Cardiovascular Events: Results of a 4-Year Follow-Up Study.

Authors:  L Turgunova; B Baidildina; Y Laryushina; B Koichubekov; A Turmukhambetova; L Akhmaltdinova
Journal:  Cardiol Res Pract       Date:  2020-06-23       Impact factor: 1.866

Review 2.  The role of meningeal populations of type II innate lymphoid cells in modulating neuroinflammation in neurodegenerative diseases.

Authors:  Sherry Sin-Hang Yeung; Yuen-Shan Ho; Raymond Chuen-Chung Chang
Journal:  Exp Mol Med       Date:  2021-09-06       Impact factor: 12.153

3.  Specific matrix metalloproteinases and calcification factors are associated with the vulnerability of human carotid plaque.

Authors:  Zhou-Ying Guo; Bai Zhang; Yan-Hong Yan; Shang-Shang Gao; Jing-Jing Liu; Lan Xu; Pin-Jing Hui
Journal:  Exp Ther Med       Date:  2018-07-09       Impact factor: 2.447

Review 4.  Scavenger Receptors as Biomarkers and Therapeutic Targets in Cardiovascular Disease.

Authors:  Gary A Cuthbert; Faheem Shaik; Michael A Harrison; Sreenivasan Ponnambalam; Shervanthi Homer-Vanniasinkam
Journal:  Cells       Date:  2020-11-10       Impact factor: 6.600

Review 5.  Identification Markers of Carotid Vulnerable Plaques: An Update.

Authors:  Yilin Wang; Tao Wang; Yumin Luo; Liqun Jiao
Journal:  Biomolecules       Date:  2022-08-28

6.  Sex-specific and opposite modulatory aspects revealed by PPI network and pathway analysis of ischemic stroke in humans.

Authors:  Yan Lv; X Y He; Dongguo Li; Tao Liu; G Q Wen; Junfa Li
Journal:  PLoS One       Date:  2020-01-03       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.